From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Novartis Receives FDA Approval for First Cell-Culture Influenza Vaccine

by Global Biodefense Staff
November 23, 2012

The Food and Drug Administration (FDA) this week approved the use of Novartis’ Flucelvax vaccine in adults, becoming the first cell-culture-derived influenza vaccine to receive approval in the United States. 

Traditional vaccine production methods have relied on egg-based production, requiring a large number of fertilized chicken eggs to grow strains and often needing several months for organization of egg supplies, virus incubation and actual production before a vaccine is delivered to physicians or pharmacies. 

Cell-culture technology utilizes a well-characterized mammalian cell line to grow virus strains, providing an avenue to more easily meet surge capacity needs in response to an epidemic. Cells can be frozen and stored in advance of an epidemic, or developed rapidly in response to an urgent public health need. 

Cell-culture technology is successfully used to manufacture other vaccines, including those distributed during the H1N1 pandemic, as well as vaccines for polio, rubella and hepatitis A. 

“Modern cell-culture technology will likely become the new standard for influenza vaccine production and we are proud to lead the way,” said Andrin Oswald, Division Head, Novartis Vaccines and Diagnostics.

The US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS, BARDA) has provided partial funding to Novartis for the development of the cell-culture manufacturing technology, as well as for construction of a state-of-the-art production facility in Holly Springs, N.C. The Novartis facility enhances domestic pandemic preparedness capabilities and is the first of its kind in the US.

From Our Partners
Tags: ASPRBARDAHHSInfluenzaVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC